PDCD1 and hematologic disorder: Novel agents developed to block immune checkpoint pathways which contribute to tumor tolerance, particularly Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and Programmed cell death-1 (PD-1), have been shown to be effective in solid tumor oncology and have now been investigated in hematologic malignancies [26].